본문 바로가기
KERD
논문KCI 등재

한국인 정신분열병 환자에서 비정형 항정신병 약물의 치료반응과 체중증가의 관련성에 대한 연구

Association between the Weight Gain and Treatment Response to Atypical Antipsychotics in Korean Patients with Schizophrenia

이민수|이화영|함병주|이재병
대한생물정신의학회 (The Korean Society Of Biological Psychiatry)|2011.11|생물정신의학 (Journal of Korean Society of Biological Psychiatry)|제18권 제4호|pp. 225-231

2

조회

0

다운로드

0

인용

0

참고문헌

주제분류정신과학

초록

Objectives :Atypical antipsychotics show better treatment efficacy, safety and tolerability than typical antipsychotics. Among the adverse events observed during treatment with antipsychotics, extrapyramidal syndrome (EPS) and negative symptoms has been greatly reduced. But still, weight gain is receiving growing attention. The aim of this study was to investigate the association between therapeutic response to atypical antipsychotics and weight gain in admission status. Methods : The study was conducted for Korean inpatients with schizophrenia in a university hospital in Seoul, between Jan 2006 and Dec 2010. Data was collected by reviewing the medical record of 39 consecutively hospitalized patients with Schizophrenia (DSM-IV) at a university hospital. Positive and Negative Symptom Scale (PANSS), Body Mass Index (BMI) and body weights were measured. Results : No significant difference was observed for sex, age, illness onset age, family history of schizophrenia, numbers of hospitalization before treatment, educational years, marriage status, occupational status and subtype of schizophrenia between weight gainers and non-weight gainers. Regarding treatment response to atypical antipsychotics, weight gainers show significantly more PANSS decrease than non-weight gainers during admission period. Conclusions : Our findings suggest that it appears to be more likely to respond to atypical antipsychotics in weight gainers than non-weight gainers (that weght gainers appear to be more likely to respond to atypical antipsychotics than non-weight gainers). These results show that the antipsychotic- induced body weight gain is associated with therapeutic response of antipsychotics in Korean inpatients with schizophrenia.

Abstract

Objectives :Atypical antipsychotics show better treatment efficacy, safety and tolerability than typical antipsychotics. Among the adverse events observed during treatment with antipsychotics, extrapyramidal syndrome (EPS) and negative symptoms has been greatly reduced. But still, weight gain is receiving growing attention. The aim of this study was to investigate the association between therapeutic response to atypical antipsychotics and weight gain in admission status. Methods : The study was conducted for Korean inpatients with schizophrenia in a university hospital in Seoul, between Jan 2006 and Dec 2010. Data was collected by reviewing the medical record of 39 consecutively hospitalized patients with Schizophrenia (DSM-IV) at a university hospital. Positive and Negative Symptom Scale (PANSS), Body Mass Index (BMI) and body weights were measured. Results : No significant difference was observed for sex, age, illness onset age, family history of schizophrenia, numbers of hospitalization before treatment, educational years, marriage status, occupational status and subtype of schizophrenia between weight gainers and non-weight gainers. Regarding treatment response to atypical antipsychotics, weight gainers show significantly more PANSS decrease than non-weight gainers during admission period. Conclusions : Our findings suggest that it appears to be more likely to respond to atypical antipsychotics in weight gainers than non-weight gainers (that weght gainers appear to be more likely to respond to atypical antipsychotics than non-weight gainers). These results show that the antipsychotic- induced body weight gain is associated with therapeutic response of antipsychotics in Korean inpatients with schizophrenia.

참고문헌 (36)

  1. David SR, "The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia", Clin Ther, 22, pp.1085~1096 (2000)
  2. Tollefson GD, "Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial", Am J Psychiatry, 154, pp.457~465 (1997)
  3. Rege S, "Antipsychotic induced weight gain in schizophrenia: mechanisms and management", Aust N Z J Psychiatry, 42, pp.369~381 (2008)
  4. Casey DE, "The relationship of pharmacology to side effects", J Clin Psychiatry, 58(10), pp.55~62 (1997)
  5. Allison DB, "Antipsychotic-induced weight gain: a comprehensive research synthesis", Am J Psychiatry, 156, pp.1686~1696 (1999)
  6. Ganguli R, "Weight gain associated with antipsychotic drugs", J Clin Psychiatry, 60(21), pp.20~24 (1999)
  7. Lieberman JA, "Effectiveness of antipsychotic drugs in patients with chronic schizophrenia", N Engl J Med, 353, pp.1209~1223 (2005)
  8. Weiden PJ, "Obesity as a risk factor for antipsychotic noncompliance", Schizophr Res, 66, pp.51~57 (2004)
  9. Theisen FM, "Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication", J Psychiatr Res, 35, pp.339~345 (2001)
  10. Brixner DI, "Naturalistic impact of second-generation antipsychotics on weight gain", Ann Pharmacother, 40, pp.626~632 (2006)
  11. Czobor P, "Antipsychotic-induced weight gain and therapeutic response: a differential association", J Clin Psychopharmacol, 22, pp.244~251 (2002)
  12. Ascher-Svanum H, "Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia", BMC Psychiatry, 5, pp.3~ (2005)
  13. Garyfallos G, "Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels", Eur Psychiatry, 18, pp.320~321 (2003)
  14. American Diabetes Association, "Consensus development conference on antipsychotic drugs and obesity and diabetes", Diabetes Care, 27, pp.596~601 (2004)
  15. Kay SR, "The positive and negative syndrome scale (PANSS) for schizophrenia", Schizophr Bull, 13, pp.261~276 (1987)
  16. Woods SW, "Chlorpromazine equivalent doses for the newer atypical antipsychotics", J Clin Psychiatry, 64, pp.663~667 (2003)
  17. MÜller MJ, "Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia", J Clin Psychopharmacol, 22, pp.554~560 (2002)
  18. Simpson GM, "Double-blind study of clozapine dose response in chronic schizophrenia", Am J Psychiatry, 156, pp.1744~1750 (1999)
  19. Tzimos A, "Safety and tolerability of oral paliperidone extended- release tablets in elderly patients with schizophrenia: a doubleblind, placebo-controlled study with six-month open-label extension", Am J Geriatr Psychiatry, 16, pp.31~43 (2008)
  20. Jalenques I, "Weight gain and clozapine", Encephale, 22(3), pp.77~79 (1996)
  21. Wetterling T, "Weight gain: side effect of atypical neuroleptics", J Clin Psychopharmacol, 19, pp.316~321 (1999)
  22. Kalucy RS, "Drug-induced weight gain", Drugs, 19, pp.268~278 (1980)
  23. Bustillo JR, "Differential effect of clozapine on weight: a controlled study", Am J Psychiatry, 153, pp.817~819 (1996)
  24. Bai YM, "Weight gain among patients on clozapine", Psychiatr Serv, 50, pp.704~705 (1999)
  25. Shrivastava A, "Weight-gain in psychiatric treatment: risks, implications, and strategies for prevention and management", Mens Sana Monogr, 8, pp.53~68 (2010)
  26. Wetterling T, "Bodyweight gain with atypical antipsychotics", A comparative review, 24, pp.59~73 (2001)
  27. Stanton JM, "Weight gain associated with neuroleptic medication: a review", Schizophr Bull, 21, pp.463~472 (1995)
  28. Baptista T, "Body weight gain induced by antipsychotic drugs: mechanisms and management", Acta Psychiatr Scand, 100, pp.3~16 (1999)
  29. Jin H, "Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin", Schizophr Res, 100, pp.70~85 (2008)
  30. Chengappa KN, "Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions", J Clin Psychiatry, 60, pp.373~378 (1999)
  31. Jaffe AB, "Efficacy and effectiveness of first- and secondgeneration antipsychotics in schizophrenia", J Clin Psychiatry, 64(17), pp.3~6 (2003)
  32. Stroup TS, "Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study", Am J Psychiatry, 164, pp.415~427 (2007)
  33. Taylor M, "Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study", J Clin Psychiatry, 69, pp.240~245 (2008)
  34. Essock SM, "Clozapine's effectiveness for patients in state hospitals: results from a randomized trial", Psychopharmacol Bull, 32, pp.683~697 (1996)
  35. Wirshing DA, "Novel antipsychotics: comparison of weight gain liabilities", J Clin Psychiatry, 60, pp.358~363 (1999)
  36. Marder SR, "The Mount Sinai conference on the pharmacotherapy of schizophrenia", Schizophr Bull, 28, pp.5~16 (2002)

관련 논문AI추천

입원 치료 중인 조현병 환자의 비만도와 정신병리함웅, 박성용, 백인호, 송명선, 홍계현대한신경정신의학회 · 신경정신의학2015 · 제54권 제2호조현병 환자에서 항정신약물이 대사지표에 미치는 영향 조사 - 1년 추적연구박은경, 윤해주, 이종일, 임선진, 정선화대한조현병학회 · 대한조현병학회지2015 · 제18권 제2호항정신병약물을 처음으로 사용하는 초발 정신증 환자에서 나타나는 체중 및 대사성 지표의 변화 : 후향적 연구강제욱, 공보금, 김민걸, 김성진, 김우진, 김정은, 김현정, 문정준, 박민경, 심주철, 정도운대한생물치료정신의학회 · 생물치료정신의학2011 · 제17권 제2호정신분열병 환자에서 항정신병 약물의 치료 반응과 장기 체중 증가김희철, 정성원대한생물치료정신의학회 · 생물치료정신의학2007 · 제13권 제1호체중증가 발생 가능성에 따른 항정신병약물 네 군 간의 정신분열병 환자의 주관적 삶의 질 비교 연구강권영, 강시현, 김경훈, 김권곤, 소민아, 안길준, 이가회, 이종일대한신경정신의학회 · 신경정신의학2011 · 제50권 제5호조현병 환자에서 비전형항정신병약물 사용시 대사지표에 미치는 영향 조사 : 3년 추적연구박은경, 배하현, 윤해주, 이종일대한조현병학회 · 대한조현병학회지2017 · 제20권 제1호

이 간행물의 다른 논문 (13건)

주요우울증에서 스트레스, 염증반응, 신경조직발생김용구pp. 169-175우울장애의 신경생물학적 최신 지견 : 세로토닌 전달체에 대한 영상 유전학적 연구를 중심으로함병주pp. 176-180우울증의 후생유전적 기전의 역할김재원, 윤봉준pp. 181-188우울장애의 신경생물학적 기전으로서 세포 내 신호전달계의 역할김세현pp. 189-196Subsyndromal Anxiety Disorder의 특징과 임상적 중요성강남인, 양종철pp. 197-202
원문 보기